Molecular genetic analyses are a key component of modern tumor diagnostics and support you at every stage of patient care. We accompany you from genetic clarification at initial diagnosis to therapy recommendations, monitoring, and follow-up. We bring tomorrow’s precision oncology to today’s patients.
We usually deliver reports within two to three weeks. The results are precise, clearly structured, and can be directly integrated into therapy planning. Our analyses are based on the latest state of medical genetics and are continually updated in accordance with new scientific findings. If you have any questions regarding indications, sample material, or interpretation, our experts support you personally, competently and reliably
Your patients are insured in Germany? Our colleagues at the Zentrum für Humangenetik Tübingen will gladly support you!
We provide optimal support from diagnosis to monitoring with our somatic tumor analyses
Genetic Tumor Diagnostics
CancerEssential® identifies key genetic alterations in common solid tumors such as lung, breast, or colorectal cancer quickly and reliably.
Using indication-specific gene sets, we analyze all relevant genes of a tumor type in a single step. This makes CancerEssential® an efficient diagnostic solution. The detection of specific mutations in tumor tissue forms the basis for selecting an approved targeted therapy.
CancerPrecision® provides a comprehensive molecular genetic profile of the individual tumor. This is the basis for personalized treatment decisions.
The analysis is based on a tumor–normal tissue comparison and precisely detects all genetic alterations that influence tumor behavior, therapy response, or resistance mechanisms – including key biomarkers such as MSI, TMB, and HRD. The medical report includes not only a comprehensive molecular genetic tumor profile, but also potential therapy options, supporting you in making informed, personalized treatment decisions.
Genetic Tumor Diagnostics
Add-Ons
In addition to CancerPrecision®
CancerFusionRx® is the ideal complement to CancerPrecision® when a gene fusion is suspected of driving the tumor disease. Gene fusions are therapeutically relevant: therapies targeting these specific genetic alterations are being used with increasing frequency.
Using our unique method, we precisely detect therapy-relevant gene fusions at the RNA level. In the medical report, we provide all identified gene fusions along with a list of potential therapy options involving EMA- or FDA-approved drugs.
Specific Therapy Recommendations
CancerAdvice® provides well-founded therapy recommendations based on molecular genetic findings. Our interdisciplinary team of experts conducts the comprehensive research and evaluation of all relevant treatment options.
You receive clear recommendations on approved therapies (in-label), off-label options, and current clinical trials. All options are transparently categorized according to level of evidence, approval status (EMA/FDA), and study availability. In this way, we aim to support you in proposing the most suitable targeted treatment options for your patients.
Diagnostics for Personalized Immunotherapies
CancerNeo® supports you in the development of personalized cancer vaccines – for example, within clinical studies or individual therapy concepts.
Through comprehensive genetic analyses, we identify the most relevant somatic mutations and highly expressed target structures for an effective vaccine design.
Monitoring and Follow-Up
CancerMRD is a personalized and non-invasive monitoring approach used after completing tumor therapy. By monitoring minimal residual disease over time, our service enables to detect potential recurrences far earlier than traditional imaging and to asses therapy response reliably.
We initially create an individual tumor fingerprint based on tumor-normal tissue comparison. During follow-up, we examine blood samples for cell-free tumor DNA and compare the results with this profile. Blood collection is simple, can be repeated easily, and is particularly suitable for long-term disease monitoring.
By analyzing cell-free tumor DNA from liquid biopsy, CancerDetect® detects the most common relevant hotspot mutations – for example, for therapy monitoring, early detection of resistance development, or diagnostics when no tumor tissue is available.
The simple, non-invasive sample collection enables reliable monitoring throughout the entire course of therapy.
Frequently Asked Questions
Topic-specific
Sample Shipment & Costs
Result
Further Information
Webinar: Discover the Power of Modern Tumor Diagnostics
Genetic tumor diagnostics can save lives
Downloads
Contact Us
Do you have a question, or are you interested in our service?
Diagnostic Support
We will assist you in selecting the diagnostic strategy – for each patient.
